Helixmith (084990) Fundamentals 2026 — Revenue Analysis | SniperIQ
Helixmith (084990) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩152.6B, trading at ₩3315.00 on the KOE. This SniperIQ fundamentals page covers Helixmith's valuation, profitability (net margin -13.7%), revenue (₩2.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Helixmith's market cap?
Helixmith (084990) has a market capitalization of approximately ₩152.6B, trading at ₩3315.00 on the KOE. Market cap moves with the live share price.
What is Helixmith's P/E ratio?
Helixmith's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Helixmith?
Helixmith runs a net profit margin of -13.7%, a gross margin of -51.6%, and an operating margin of -415.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Helixmith generate?
Helixmith reported revenue of ₩2.6B for fiscal year 2025, with net income of -₩435M and earnings per share (EPS) of -9.45. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Helixmith pay a dividend?
Helixmith does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Helixmith financially healthy?
Helixmith carries a debt-to-equity ratio of 0.00x and a current ratio of 107.85x, with a market beta of 0.08. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Helixmith a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Helixmith (084990) the key facts are: market cap ₩152.6B, revenue ₩2.6B, 52-week range 2795-9960. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Helixmith's full fundamentals live
Get Helixmith's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.